Natasha Krishnadas
@Nat_Krishnadas
Followers
193
Following
431
Media
7
Statuses
94
Neurologist | Postdoc | Neuroimaging | Neurodegenerative diseases | Dementia | Tau | Views are my own
Joined May 2022
Pleased to have contributed to this review on FTD and the differential diagnoses, from a real-world quaternary memory clinic. Have a listen to this podcast with Prof Brodtmann:.
Neurology Podcast: Dr. Trey Bateman and Dr. Amy Brodtmann discuss the complexities of diagnosing FTD and related disorders. Listen now: .#NeuroTwitter #Dementia @RenegadeSynapse
0
0
1
RT @janealty1: 💫Thank you to everyone for sharing their time, expertise and experience of #PD for the NEW 🌟PARKINSONS MOOC 🌟Together we can….
mooc.utas.edu.au
Grow your knowledge and understanding of Parkinson’s Disease. Discover the Parkinson’s MOOC, a groundbreaking online course created by the Wicking Dementia Centre and Menzies Research Institute at...
0
13
0
RT @DrAnitaGoh: Calling all Victorians from #Chinese backgrounds! .We are recruiting participants for a new 8-week program called 'Befriend….
0
4
0
RT @NeurologyCP: Frontotemporal Dementia Differential Diagnosis in Clinical Practice: A Single-Center Retrospective Review of Frontal Behav….
0
17
0
RT @Brain1878: Spitz et al. study long-term survivors of moderate-severe TBI, and show that elevated plasma levels of biomarkers related to….
0
8
0
RT @AzadehFeizpour: Pleased to present our paper @eBioMedicine, on the Lumipulse plasma pTau217 assay. Lumipulse-G platform → large global….
0
2
0
RT @PEERSPIA: 📢 Save the Date! Join us on Thursday, November 21 from 5:00 to 5:30 pm ET for our Journal Club!.💻Register here: https://t.co/….
0
5
0
RT @RoweLab_aus: We at Rowe Lab are very proud that our PET expert, @vincentDore2 was awarded the prestigious de Leon Prize, as senior auth….
0
2
0
RT @JAMANeuro: Quantitative tau PET and tau PET visual reads show the greatest promise as a stand-alone prognostic marker for clinical prog….
0
39
0
Excited to attend the Australian Dementia Research Forum, virtually! #ADRF - here's to conferences that are continuing with a hybrid format @ADNeT_Australia @Momademia
1
2
2
Not long to go now! Don't forget to register for this unique opportunity to meet Prof Lautenschlager and likeminded researchers in #Neuroscience #Alzheimers hosted by @DrKaramacoska and @ISTAART.
0
1
0
Is there clinical evidence for the use of GLP-1 receptor agonists in #Alzheimers disease? Our recent systematic review suggests current data is limited, but upcoming RCT's may yield more insights: #ADresearch @vincentDore2 @RoweLab_aus.
journals.sagepub.com
Background: Alzheimer’s disease (AD) is the most common cause of dementia. While preclinical studies have shown benefits of glucagon-like peptide 1 receptor ago...
0
2
7
RT @OttoyJulie: So excited and grateful to be the plenary speaker for the @NeuroimagingPIA year in review talk 🧠at AIC 2024 in Philadelphi….
docs.google.com
Dear friends, colleagues, and members of the Neuroimaging PIA, I am incredibly honored and excited to be invited to give the opening plenary talk at the next Alzheimer’s Imaging Consortium (AIC) on...
0
8
0
RT @Doctor_Samba: We want to know about gaps, barriers+opportunities for #YOD. Please complete our surveys+repost! .People living with YO….
0
11
0
RT @oliviamaurice_: 🌟 Don't miss out! 🌟 Sign up now for the Mentoring Club session 📚✨ on May 29 hosted by @PEERSPIA and @ISTAART. Register….
0
5
0
RT @AzadehFeizpour: Exciting results!🧠✨Our latest study showcases that plasma P217+tau can distinguish Intermediate or Advanced stage #Alzh….
medrxiv.org
Background Plasma phospho-tau biomarkers, such as p217+tau, excel at identifying Alzheimer’s Disease (AD) neuropathology. However, questions remain regarding their capacity to inform AD biological...
0
2
0
RT @wagnersbrum: We evaluated the biological variation of 🩸 p-tau (217, 231, 181), Aβ, NfL and GFAP weekly over 10 weeks in healthy individ….
0
53
0
RT @vincentDore2: 🔥 Hot off the press: Utilizing 18F-AV-133 VMAT2 PET Imaging to Monitor Progressive Nigrostriatal Degeneration in Parkinso….
0
5
0